According to another meta-analysis [63], GLP-1 agonists were associated with a reduction in the incidence of major adverse cardiac events (MACE), non-fatal myocardial infarction (MI), cardiovascular death, and hospitalizations for heart failure. Here, GCG is linked to myocardial infarction.